LTS Lohmann Expands CDMO Services into Ophthalmic Drug Delivery at New Jersey Facility
Key Insights
LTS Lohmann Therapie-Systeme AG announced expansion of its CDMO portfolio to include ophthalmic drug delivery solutions, leveraging manufacturing capabilities at its Lakewood, New Jersey facility.
The company will initially focus on product development through clinical manufacturing of sterile ophthalmic products (search) in preservative-free multidose devices for chronic and acute eye conditions (search).
LTS plans to offer comprehensive end-to-end CDMO services for ophthalmic drug products, from formulation development through commercial manufacturing, supporting both U.S. and international regulatory requirements.
LTS Lohmann Therapie-Systeme AG, a leading pharmaceutical technology company specializing in advanced drug delivery systems, announced the expansion of its contract development and manufacturing organization (CDMO) services to include ophthalmic drug delivery solutions. The new capabilities will be housed at the company's Lakewood, New Jersey facility, marking a strategic move into the specialized eye care therapeutics market.
Initial Focus on Sterile Manufacturing
The expanded service offering initially targets product development through clinical manufacturing of sterile ophthalmic products (search), specifically those filled in preservative-free multidose devices. This approach addresses the unique requirements of eye treatments, where sterility and patient safety are paramount concerns.
LTS is leveraging its established commercial aseptic manufacturing capabilities in nasal sprays and vials to meet the stringent quality and regulatory demands of ophthalmic treatments. The company's existing infrastructure positions it to serve products designed for both chronic and acute eye conditions (search).
Comprehensive Service Vision
Building on decades of experience in drug delivery technologies, LTS plans to develop comprehensive end-to-end CDMO services for ophthalmic drug products. The planned services will span from formulation development through commercial manufacturing, with all activities conducted in compliance with global regulatory standards to support both U.S. and international market requirements.
"Ophthalmic drug delivery presents unique challenges in terms of sterility, efficacy, and patient safety," said Bas van Buijtenen, CEO at LTS. "Our aseptic manufacturing capabilities in Lakewood, are the perfect foundation to build industry-leading CDMO capabilities and capacity for ophthalmics, powering the future of drug delivery in this field in North America."
Strategic Market Positioning
The expanded CDMO services target pharmaceutical and biotech companies seeking a reliable U.S.-based manufacturing partner for ophthalmic drug delivery solutions. LTS aims to serve as a long-term partner across the entire product lifecycle by combining development expertise, sterile manufacturing infrastructure, and quality culture.
This portfolio expansion reflects LTS's strategic commitment to continuously broaden its technology and service offerings while addressing growing demand for specialized drug delivery solutions in sensitive therapeutic areas.
Company Background and Capabilities
LTS operates as a global CDMO offering end-to-end development and manufacturing services for pharmaceutical and biotech companies. The company's technology portfolio includes transdermal patches, oral thin films, nasal and sterile drug delivery products, wearable drug delivery devices, and microneedle array patches.
With over 40 commercial products and more than 50 active development programs, LTS combines expertise with patient-centric innovation to advance small molecules, biologics, and vaccines. The company operates from five global sites in the United States, Germany, and Israel, with a representative office in China.